Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment
Clinical Drug Investigation · 2024
DOI: 10.1007/s40261-024-01395-7 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Drug Investigation, 2024. Verfasst von Vassilios Aslanis und 11 weiteren Autor:innen. Beteiligte Einrichtung: Galecto Biotech AB, Ole Maaloes Vej 3, 2200, Copenhagen, Denmark. v.aslanis@gmail.com. Hauptthemen laut MEDLINE: Galectin 3. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Galecto Biotech AB.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES: Selvigaltin (GB1211), an orally available small molecule galectin-3 inhibitor developed as a treatment for liver fibrosis and cirrhosis, was evaluated to assess the effect of hepatic impairment on its pharmacokinetics and safety to address regulatory requirements. METHODS: GULLIVER-2 was a Phase Ib/IIa three-part study. Parts 1 and 3 had single-dose, open-label designs assessing pharmacokinetics (plasma [total and unbound] and urine), safety, and tolerability of 100 mg oral selvigaltin in participants with moderate (Child-Pugh B, Part 1) or severe (Child-Pugh C, Part 3) hepatic impairment, compared with healthy-matched participants (n = 6 each). RESULTS: All participants received selvigaltin and completed the study. No adverse events were reported. The median time to reach maximum total plasma concentration following drug administration was of 3.49 and 4.00 h post-dose for Child-Pugh B and C participants, respectively; comparable with controls. Total plasma exposure was higher for participants with hepatic impairment compared with controls. Whilst maximum plasma concentration (Cmax) was unaffected in Child-Pugh B participants, area under the plasma concentration-time curve from time zero to infinity (AUC∞) increased by ~ 1.7-fold compared with controls, and half-life was prolonged (geometric mean 28.15 vs 16.38 h). In Child-Pugh C participants, Cmax increased by ~ 1.3-fold, AUC∞ increased by ~ 1.5-fold, and half-life was prolonged (21.05 vs 16.14 h). No trend was observed in plasma unbound fractions or urinary excretion of unchanged selvigaltin in either group. CONCLUSION: Hepatic impairment increased selvigaltin exposure without safety concerns. These data can inform dose recommendations for future clinical programmes. TRIAL REGISTRATION: Clinicaltrials.gov NCT05009680.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Galecto Biotech AB, Ole Maaloes Vej 3, 2200, Copenhagen, Denmark. v.aslanis@gmail.com.
- Galecto Biotech AB, Ole Maaloes Vej 3, 2200, Copenhagen, Denmark.
- MC Comac Medical Ltd, Sofia, Bulgaria.
- Ungell ADME Consulting AB, Näsbovägen, Västra Frölunda, Sweden.
Förderung
- Galecto Biotech AB
Zitieren
APA
Aslanis, V., Gray, M., Slack, R. J., Zetterberg, F. R., Tonev, D., Phung, Smith, B., Jacoby, B., Schambye, H., Krastev, Z., Ungell, A. L., & Lindmark, B. (2024). Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment. Clinical Drug Investigation. https://doi.org/10.1007/s40261-024-01395-7
Vancouver
Aslanis V, Gray M, Slack RJ, Zetterberg FR, Tonev D, Phung, et al. Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment. Clinical Drug Investigation. 2024. doi:10.1007/s40261-024-01395-7
BibTeX
@article{Aslanis2024,
author = {Aslanis, Vassilios and Gray, Michael and Slack, Robert J and Zetterberg, Fredrik R and Tonev, Dimitar and Phung, De and Smith, Becky and Jacoby, Brian and Schambye, Hans and Krastev, Zahari and Ungell, Anna-Lena and Lindmark, Bertil},
title = {Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment},
journal = {Clinical Drug Investigation},
year = {2024},
doi = {10.1007/s40261-024-01395-7}
}
EUVIMED